Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous immunoglobulin replacement therapy for persistent COVID-19 in patients with B-cell impairment
KCT0009239Phase 2Terminated
- Sponsor
- Korea Disease Control and Prevention Agency
- Start
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of immune globulin in coronavirus disease 2019 (COVID-19), sponsored by Korea Disease Control and Prevention Agency. Started Apr 2024; status: terminated.
02
Drugs
immune globulin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on KCT0009239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009239.